Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This study will help find out if lenvatinib and gefitinib is a safe and useful combination for treating patients with lenvatinib resistant hepatocellular carcinoma.
Hepatocellular Carcinoma|Molecular Targeted Therapy
DRUG: Lenvatinib and Gefitinib
Progression free survival, The estimation of time from start of combination therapy to progression of disease, 6 months after the last subject is enrolled
Overall survival, The time between initial combination therapy and the patient's death of any cause or most recent follow-up., 6 months after the last subject is enrolled|Safety endpoint, Statistically describe the proportion of adverse events after treatment for each patient, 6 months after the last subject is enrolled
This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This study will help find out if lenvatinib and gefitinib is a safe and useful combination for treating patients with lenvatinib resistant hepatocellular carcinoma.